Product Image

Contributor Information

  • Name Martin Humphries
  • Institute University of Manchester

Tool Details

  • Tool name: Anti-CD49b [31H4]
  • Alternate names: Integrin Subunit Alpha 2; Alpha 2 Subunit Of VLA-2 Receptor; Platelet Membrane Glycoprotein Ia; CD49 Antigen-Like Family Member B; Collagen Receptor; CD49B; GPIa; Very Late Activation Protein 2 Receptor; Alpha-2 Subunit; Human Platelet Alloantigen System; Platelet Glycoprotein GPIa; VLA-2 Subunit Alpha; CD49b Antigen; HPA-5; VLA-2; VLAA2; BR
  • Clone: 31H4
  • Tool type: Antibodies
  • Tool sub-type: Primary antibody
  • Class: Monoclonal
  • Conjugate: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; FACS ; IP
  • Description: CD49b also known as integrin alpha-2, VLA-2 subunit alpha or collogen receptor. CD49b is a 1181 amino acid Â?130 kDa single pass type-1 transmembrane glycoprotein which forms a heterodimer with integrin beta-1 and mediates the adhesion of platelets and other cell types to the extracellular matrix. Loss of the encoded protein is associated with bleeding disorder platelet-type 9. Antibodies against this protein are found in several immune disorders, including neonatal alloimmune thrombocytopenia.
  • Immunogen: Purified human b1 integrin preparation from HT1080 fibrosarcoma cell extract.
  • Isotype: IgG1
  • Research area: Cell biology; Cell signaling and signal transduction; Immunology
  • Myeloma used: P3X63Ag8.653

  • For Research Use Only

Target Details

  • Target: Integrin alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)
  • Target background: CD49b also known as integrin alpha-2, VLA-2 subunit alpha or collogen receptor. CD49b is a 1181 amino acid 130 kDa single pass type-1 transmembrane glycoprotein which forms a heterodimer with integrin beta-1 and mediates the adhesion of platelets and other cell types to the extracellular matrix. Loss of the encoded protein is associated with bleeding disorder platelet-type 9. Antibodies against this protein are found in several immune disorders, including neonatal alloimmune thrombocytopenia.

Application Details

  • Application: ELISA ; FACS ; IP

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15°C to -25°C
  • Shipping conditions: Shipping at 4°C

Documentation

Related Tools

Product Image

Anti-CD81 [2s113]

#154250
Product Image

Anti-FCGR2 [KB61]

#151359
Product Image

Anti-Nab3p [2F12]

#158406

References

  • •  Tanaka et al. 2012. Int J Oncol. 41(5):1837-44. PMID: 22923148.
  • •  Differential sensitivity to paclitaxel-induced apoptosis and growth suppression in paclitaxel-resistant cell lines established from HEC-1 human endometrial adenocarcinoma cells.
  • •  Tanaka et al. 2012. Oncol Rep. 28(1):330-6. PMID: 22552543.
  • •  Impaired death-associated protein kinase-mediated survival signals in 5-fluorouracil-resistant human endometrial adenocarcinoma cells.
  • •  Tanaka et al. 2010. Int J Oncol. 37(1):125-31. PMID: 20514404.
  • •  Establishment and characterization of novel human uterine leiomyosarcoma cell lines.
  • •  Tanaka et al. 2009. Int J Mol Med. 23(2):173-80. PMID: 19148540.
  • •  Remodeling of the human endometrial epithelium is regulated by laminin and type IV collagen.
  • •  Tanaka et al. 2008. Int J Mol Med. 22(5):581-7. PMID: 18949377.
  • •  Autocrine/paracrine regulation of human endometrial stromal remodeling by laminin and type IV collagen.
  • •  Tanaka et al. 2008. Oncol Rep. 20(1):13-23. PMID: 18575713.
  • •  Experimental characterization of recurrent ovarian immature teratoma cells after optimal surgery.
  • •  Tanaka et al. 2006. Oncol Rep. 15(4):939-47. PMID: 16525683.
  • •  Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro.
  • •  Tanaka et al. 2005. Oncol Rep. 14(4):941-8. PMID: 16142355.
  • •  Reduced radiosensitivity and increased CD40 expression in cyclophosphamide-resistant subclones established from human cervical squamous cell carcinoma cells.